MarketCap
Facebook
X
TelegramGeschäftsbericht 2024
hinzugefügt 24.01.2026
Grifols, S.A. Betriebsaufwand 2011-2026 | GRFS
Betriebsaufwand Jährlich Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.64 B | 1.77 B | 1.56 B | 1.42 B | 1.28 B | 1.22 B | 1.06 B | 1.15 B | 973 M | 961 M | 842 M | 682 M | 670 M | 1.05 B |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.77 B | 670 M | 1.16 B |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
GlaxoSmithKline plc
GSK
|
16.2 B | $ 48.98 | 0.68 % | $ 173 B |  Britain |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K |  USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M |  Canada |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.51 | 7.34 % | $ 8.45 B |  Australia |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 25.92 | -0.86 % | $ 1.26 B | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Galapagos NV
GLPG
|
709 M | $ 34.61 | 0.61 % | $ 2.69 B |  Belgium |
 |
Ultragenyx Pharmaceutical
RARE
|
595 M | $ 24.45 | 4.49 % | $ 2.21 B | USA |
 |
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 3.1 | 4.49 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 116.27 | -1.86 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 235.41 | 2.95 % | $ 5 B |  Danmark |
 |
BioXcel Therapeutics
BTAI
|
107 M | $ 1.84 | 1.66 % | $ 4.66 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 9.74 | -1.37 % | $ 1.55 B | Britain |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.66 | -1.85 % | $ 16.7 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
731 M | $ 67.49 | -3.02 % | $ 9.03 B | USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 4.51 | 8.41 % | $ 9.81 B | Israel |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Coherus BioSciences
CHRS
|
231 M | $ 2.04 | 28.3 % | $ 192 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
5.39 B | $ 171.89 | -1.1 % | $ 25 B | USA |
 |
Bio-Path Holdings
BPTH
|
15.8 M | - | - | $ 100 K | USA |
 |
BioVie
BIVI
|
18.1 M | $ 1.2 | -3.7 % | $ 1.77 M | USA |